综合电商模板

R&D  SC032  StemXVivo Cardiomyocyte Differentiation Kit

产品编号 SC032| rndsystems

StemXVivo Cardiomyocyte Differentiation Kit

For differentiation of pluripotent stem cells into cardiomyocytes

产品介绍

Kit Summary

For the directed differentiation of human pluripotent stem cells into cardiomyocytes

Key Benefits

Optimized components ensure highly enriched cardiomyocyte populations

Reproducible differentiation protocols translate into cost and time savings

Maximizes workflow efficiency by standardizing cardiomyocyte differentiation

Validated for drug toxicity and small molecule screening

Why Use Pre-mixed Differentiation Cocktails when Differentiating Human Pluripotent Stem Cells into Cardiomyocytes?

The StemXVivo Cardiomyocyte Differentiation Kit uses high-quality specialized media and pre-mixed differentiation cocktails to maximize differentiation efficiency and ensure the consistent and reliable generation of scalable amounts of cardiomyocytes. Using optimized reagents and a straightforward protocol, this kit provides a reproducible method for obtaining high-yields of healthy cardiomyocytes while minimizing the cost and time involved in the differentiation process.

Cardiomyocyte differentiation in vitro:

Uses premixed differentiation cocktails to optimally drive reproducible differentiation of pluripotent stem cells into cardiomyocytes.

Yields a highly enriched and healthy cardiomyocyte population.

Produces cardiomyocytes that express Cardiac Troponin T and contract synchronously.

Can be part of small molecule and drug toxicity screening workflows.

Precautions

This product contains human transferrin. This transferrin was tested at the donor level using an FDA licensed method and found to be non-reactive for anti-HIV-1/2 and Hepatitis B surface antigen. As no testing can offer complete assurance of freedom from infectious agents, these reagents should be handled as if capable of transmitting infection.

Kit Contents

This kit contains the following reagents to drive pluripotent stem cell differentiation into cardiomyocytes and an antibody to verify differentiation status.

Stem Cell Qualified RGF BME, Pathclear

Cardiomyocyte Differentiation Base Media Supplement I

Cardiomyocyte Differentiation Base Media Supplement II

Cardiomyocyte Differentiation Cocktail I

Cardiomyocyte Differentiation Cocktail II

Cardiomyocyte Differentiation Cocktail III

Anti-Human Cardiac Troponin T Antibody

The quantity of each component in this kit is sufficient to differentiate two 24-well plates, or an equivalent surface area, of pluripotent stem cells into cardiomyocytes.

Data Examples

Small Molecules Affect the Contraction Rate of Stem Cell-derived Cardiomyocytes.A rate interval graph shows fluctuations in Fluo-4 fluorescence intensity, indicative of cardiomyocyte contraction, under basal conditions (brown; untreated) and following sequential treatment with Isoproterenol (Catalog # 1747), a beta-adrenergic agonist, and Propranolol (Catalog # 0624), a beta-adrenergic antagonist. B) This table shows the contraction rate (beats per minute) of differentiated cardiomyocytes during each of the treatments in panel A. One beat equals the amount of time between two consecutive Fluo-4 intensity peaks. The concentrations of Isoproterenol and Propranolol used during the experiment are also shown.

Differentiation of Pluripotent Stem Cells into Cardiomyocytes.BG01V human embryonic stem cells were differentiated into cardiomyocytes using the media supplements included in this kit. Aside from visually observing contracting cells, commitment to the cardiomyocyte cell fate was evaluated by labeling with the Anti-Human Cardiac Troponin T antibody included in the kit. For immunocytochemistry (left panel), the cells were stained using the NorthernLights™ 557-conjugated Donkey anti-Mouse secondary antibody (R&D Systems, Catalog # NL007; red), and the nuclei were counterstained with DAPI (blue). For flow cytometry (right panel), the cells were stained using Anti-Mouse PE-conjugated secondary antibody (blue histogram; R&D Systems, Catalog # F0102B) and compared to matched isotype control (brown histogram).

BG01V human embryonic stem cells are licensed from Viacyte, Inc

Preparation and Storage

Stability & Storage

Store the unopened product at -70 ℃. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.

Background: Pluripotent Stem Cells

Embryonic stem (ES) cells are pluripotent stem cells derived from the inner cell mass of pre-implantation embryos. Induced pluripotent stem (iPS) cells can be generated by somatic cell reprogramming following the exogenous expression of specific transcription factors (Oct-3/4, KLF4, SOX2, and c-Myc). These cell types are capable of unlimited, undifferentiated proliferation in vitroand still maintain the capacity to differentiate into a wide variety of somatic cells. In this capacity, pluripotent stem cells have widespread clinical potential for the treatments of heart disease, diabetes, spinal cord injury, and a variety of neurodegenerative disorders.

R&D Systems offers a wide range of products to support pluripotent stem cell culture and differentiation. Mouse embryonic fibroblasts may be used to maintain and expand pluripotent stem cells in an undifferentiated state. We also offer defined culture media, which are specifically optimized for use with human or rodent pluripotent stem cells. In addition, R&D Systems offers a variety of products to assess differentiation status and identify specific stem cell types of interest, including panels of marker antibodies, primer pairs, multi-color flow cytometry kits, and specialized verification kits.

公司简介

R&D Systems作为全球免疫学和细胞生物学产品的领跑者，1976年创立于美国明尼苏达州。其母公司Bio-Techne（原Techne公司）于1983年在美国NASDAQ上市。

目前，R&D Systems拥有近30,000种产品，95%以上由自己研发生产。其产品包括细胞因子、ELISA试剂盒、生长因子、趋化因子、抗体、Animal-Free™蛋白、Luminex 液相芯片、多因子检测固相芯片、流式细胞分析与细胞筛选、干细胞及细胞培养等；覆盖肿瘤、发育、糖生物、内分泌、免疫、神经学、蛋白酶、信号传导等学科研究领域；且每年有近2,000种新产品不断问世，以满足不同科研工作者的研究需要。

Uante,您的科研物资战略合作伙伴！

重庆市寰宇安泰生物科技有限公司

固定电话：023-67946738

全国热线：400-8623-068